Study Summary
This is a single-arm, open-label, one center, dose escalation clinical study, to determine the safety and efficacy of infusion of autologous T cells engineered to express immune checkpoint antibody and chimeric antigen receptor targeting mesothelin in adult patients with mesothelin positive, recurrent or refractory malignant tumors.
Want to learn more about this trial?
Request More InfoInterventions
PD-1 antibody expressing mesothelin specific CAR-T cellsBIOLOGICAL
Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Ningbo No.5 Hospital (Ningbo Cancer Hospital) | Ningbo | Zhejiang | China |